| Today’s Big NewsSep 5, 2023 |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today. 
|
|
| By Conor Hale Jacob Thaysen will make the jump after serving as Agilent Technologies' president of life sciences and applied markets. He will take the top job at Illumina Sept. 25. |
|
|
|
| Philadelphia, PA |  |
|
|
By Kevin Dunleavy Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act. The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026. |
By Annalee Armstrong The world’s pharmaceutical companies are set to invest $302 billion in R&D by 2028—but what will they get in return? Fierce Biotech explores the 10 therapies with the highest potential value. |
By Gabrielle Masson The latest financing will in part go toward VGA039, an early-stage mAB being developed by Star's offshoot Vega to treat von Willebrand disease. |
|
Thursday, September 14, 2023 | 11am ET / 8am PT Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. Join industry experts to learn about innovative strategies being used to unlock challenging targets. Register now. 
|
|
By Nick Paul Taylor Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. |
By Andrea Park When PerkinElmer’s diagnostics and life sciences businesses rebranded as Revvity earlier this year, the company told Fierce Medtech that the newly streamlined structure would allow them “to get more products to the market in a much faster way.” |
By Zoey Becker The drug boosted overall survival, progression-free survival and objective response rates in patients with recurrent or metastatic cervical cancer who had disease progression on or after a front-line therapy. |
By Nick Paul Taylor Zenas BioPharma has flipped regional rights to its bifunctional monoclonal antibody obexelimab. Bristol Myers Squibb has taken the other side of the deal, paying $50 million upfront for certain Asian rights to an asset that Zenas picked up from Xencor in return for a stake in its business less than two years ago. |
By Andrea Park Two years after spinning out of the University of Oxford, Amber Therapeutics is now the proud owner of the technology that serves as the basis for its neuromodulation system. |
By Angus Liu After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. |
By Max Bayer Tonix Pharmaceuticals says its fibromyalgia treatment turned long COVID med failed to improve severe pain in patients with the post-COVID condition. However, some potential improvements in measurements of fatigue and sleep quality are guiding the company toward a new focus. |
By Ayla Ellison The Breakthroughs category of the Fierce 50 features those who have made groundbreaking discoveries that have significantly advanced medical science and transformed patient care. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more. 
|
|
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
